drugset / Trial / NCT04492488
A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG002, as well as the immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG002 in patients with HER2-positive advanced solid tumors and locally advanced or metastatic gastric/gastroesophageal junction (GEJ) cancer.
Timeline
- Start
- 2021-05-24
- Primary completion
- 2022-10-18
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TRASTUZUMAB VEDOTIN | Unknown | 2.2 mg/kg | Intravenous |
| Subject | TRASTUZUMAB VEDOTIN | Unknown | 2.6 mg/kg | Intravenous |